Successful treatment with long-acting injectable aripiprazole monohydrate for two patients with dual diagnosis - substance use disorder and psychotic disorder
Dusunen Adam - The Journal of Psychiatry and Neurological Sciences, vol.34, no.1, pp.102-106, 2021 (ESCI, Scopus, TRDizin)
- Publication Type: Article / Article
- Volume: 34 Issue: 1
- Publication Date: 2021
- Doi Number: 10.14744/dajpns.2021.00126
- Journal Name: Dusunen Adam - The Journal of Psychiatry and Neurological Sciences
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Psycinfo, TR DİZİN (ULAKBİM)
- Page Numbers: pp.102-106
- Keywords: Craving, long-acting injectable aripiprazole, substance-induced psychotic disorder, treatment
- Open Archive Collection: AVESIS Open Access Collection
- Akdeniz University Affiliated: Yes
Abstract
© 2021 Yerkure Tanitim ve Yayincilik Hizmetleri A.S.. All rights reserved.In recent years, the rate of substance-induced psychotic disorder (SIPD) has been gradually increasing. Non-compliance with treatment and substance craving are serious problems in SIPD. Novel depot antipsychotic treatments, such as long-acting injectable aripiprazole monohydrate 400 mg (LAIAM) are reported to improve treatment compliance and functionality in psychotic disorders. However, the number of studies showing the efficacy of LAIAM treatment in patients with dual diagnosis is limited. In this paper, we present two cases. The first case was diagnosed with SIPD and the other was diagnosed with psychotic disorder with a past history of profound substance use disorder. The two cases showed both clinical and functional improvement at 1-year follow-up after the initiation of LAIAM treatment. These case reports suggest that LAIAM treatment might be an effective and safe treatment option in SIPD and reduce substance craving.